Evidence map›Paper›PMID 28903312›Full record

ArticleOncotarget2017

GNP-GAPDH

Ricardo Calderon-Gonzalez, Elisabet Frande-Cabanes, Hector Teran-Navarro, José María Marimon, Javier Freire, David Salcines-Cuevas, M Carmen Fariñas, Claudia Onzalez-Rico, Marco Marradi, Isabel Garcia and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Maternal sepsis caused byBMJ case reports · 2022
    Article
  6. Review
  7. Article
  8. A Comparison Between RecombinantFrontiers in immunology · 2021
    Article
  9. A Cross-Protective Vaccine Against 4b and 1/2bFrontiers in microbiology · 2020
    Article
  10. Epitopes for Multivalent Vaccines AgainstFrontiers in cellular and infection microbiology · 2020
    Article
  11. Article
  12. Pathogens (Basel, Switzerland) · 2018
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 1 country.

Ricardo Calderon-Gonzalez *Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Elisabet Frande-Cabanes *Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Hector Teran-Navarro *Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
José María MarimonServicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Gipuzkoa y CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Javier FreireServicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
David Salcines-CuevasGrupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
M Carmen FariñasSeccion de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Claudia Onzalez-RicoSeccion de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Marco MarradiCIC biomaGUNE, and Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, Donostia-San Sebastián, Spain.
Isabel GarciaCIC biomaGUNE, and Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, Donostia-San Sebastián, Spain.
Mirian Alkorta-GurrutxagaServicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Gipuzkoa y CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Aida San Nicolas-GomezGrupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Ana Castañeda-SampedroGrupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Sonsoles Yañez-DiazServicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Soledad PenadesCIC biomaGUNE, and Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, Donostia-San Sebastián, Spain.
Carmen PunzonDiomune S.L. Parque Científico de Madrid, Madrid, Spain; Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, Spain.
Javier Gomez-RomanServicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Fernando RiveraServicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Manuel FresnoDiomune S.L. Parque Científico de Madrid, Madrid, Spain; Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, Spain.
Carmen Alvarez-DominguezGrupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
Instituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESBiogipuzkoa Health Research Institute · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESCentro de Biología Molecular Severo Ochoa · ESCentro de Investigación Biomédica en Red · ESCIC biomaGUNE · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical cases of neonatal listeriosis are associated with brain disease and fetal loss due to complications in early or late pregnancy, which suggests that microglial function is altered. This is believed to be the first study to link microglial apoptosis with neonatal listeriosis and listeriosis-associated brain disease, and to propose a new nanovaccine formulation that reverses all effects of listeriosis and confers

Indexed as

apoptosisImmune responseImmunityImmunology and Microbiology Sectionmicrogliananovaccinesneonatal listeriosistumor necrosis factor signaling

Identifiers

PMID28903312
PMCPMC5589551
OpenAlexW2739402805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.